| Name | Title | Contact Details |
|---|---|---|
Alan Smith |
Chief Technology Officer | Profile |
TCR² Therapeutics Inc. is a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer. TCR²`s proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC-T cells) specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). In preclinical studies, TRuC-T cells have demonstrated superior anti-tumor activity compared to chimeric antigen receptor T cells (CAR-T cells), while exhibiting lower levels of cytokine release.
PriorAuthNow`s powerful, secure software works with your EHR system and connects directly with all insurance carriers, making it the fastest, most economical way to submit, monitor and complete prior authorizations.
Walter Payton Cancer Fund is a Schaumburg, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
CE and IC Inc is a Burlington, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Selventa is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.